2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P5773
    Jingzhaotoxin-34 98%
    Jingzhaotoxin-34, a 35-residue polypeptide, is a neurotoxin. Jingzhaotoxin-34 inhibits tetrodotoxin-sensitive (TTX-S) sodium currents (IC50 of ~85 nM) while having no significant effects on tetrodotoxin-resistant (TTX-R) sodium currents on rat dorsal root ganglion neurons.
    Jingzhaotoxin-34
  • HY-P5786
    Heteropodatoxin-1 98%
    Heteropodatoxin-1 (HpTx1), a spider peptide toxin, is a Kv4.2 current inhibitor. Heteropodatoxin-1 also inhibits Nav1.7 and activates Nav1.9 but does not affect Nav1.8.
    Heteropodatoxin-1
  • HY-P5823
    Azemiopsin 1391936-86-9 99.31%
    Azemiopsin is a potent nicotinic acetylcholine receptor (nAChR) inhibitor with IC50s of 0.18 μM and 22 μM against T. californica nAChR and human α7 nAChR, respectively. Azemiopsin blocks acetylcholine-induced currents in Xenopus oocytes heterologously expressing human muscle-type nAChR.
    Azemiopsin
  • HY-P5914
    Wasabi Receptor Toxin 2569291-86-5 98%
    Wasabi Receptor Toxin is a cell-penetrating scorpion toxin. Wasabi Receptor Toxin is the activator for TRPA1 ion channel with EC50 in nanomolar level, and prolongs the channel open time, but reduces Ca2+ permeability. Wasabi Receptor Toxin causes thermal hypersensitivity and mechanical allodynia in rats, without triggering neurogenic inflammation.
    Wasabi Receptor Toxin
  • HY-Z8890
    Norneostigmine 16088-19-0 98.93%
    Norneostigmine is a potent inhibitor of AChE that can penetrate the blood-brain barrier. Norneostigmine can achieve a 50% inhibition rate of mouse brain AChE after 10 min treatment, which is close to the inhibitory effect of tetrahydroaminoacridine (57% at 10 min). Norneostigmine can be used to study memory disorders related to Alzheimer's disease and other memory disorders.
    Norneostigmine
  • HY-100013
    2-PCCA 1984859-71-3 98%
    2-PCCA is a racemic form of the GPR88 receptor agonist, and inhibits GPR88-mediated cAMP production, with an EC50 of 116 nM in HEK293 cells.
    2-PCCA
  • HY-100119
    Enecadin 259525-01-4 98.51%
    Enecadin is a neuroprotective agent extracted from patent US 8623823 B2.
    Enecadin
  • HY-100130
    N-[(4-Aminophenyl)methyl]adenosine 95523-13-0 ≥98.0%
    N-[(4-Aminophenyl)methyl]adenosine is a adenosine receptor inhibitor, with Ki of 29 nM for Rat ecto-5′-Nucleotidase.
    N-[(4-Aminophenyl)methyl]adenosine
  • HY-100143
    Pentiapine 81382-51-6 99.95%
    Pentiapine (CGS 10746) is a dopamine release inhibitor without binding to synaptic dopamine receptor sites.
    Pentiapine
  • HY-100166
    AP521 151227-08-6 98.96%
    AP521 is an agonist of human 5-HT1A receptor with an IC50 of 94 nM.
    AP521
  • HY-100243
    (+)-Norcisapride 202590-69-0 99.32%
    (+)-Norcisapride (Ticalopride) is a potent 5-HT4 agonist and a 5-HT3 antagonist. (+)-Norcisapride has activity in animals models of constipation.
    (+)-Norcisapride
  • HY-100244
    NS1652 1566-81-0 99.76%
    NS1652 is a reversible anion conductance inhibitor, blocks chloride channel, with an IC50 of 1.6 μM in human and mouse red blood cells.
    NS1652
  • HY-100263
    Metofenazate 388-51-2 98.73%
    Metofenazate is a selective calmodulin inhibitor.
    Metofenazate
  • HY-100275
    MK-3328 1201323-97-8 99.70%
    MK-3328 is a β-Amyloid ligand, which exhibits high binding potency with an IC50 of 10.5 nM. MK-3328 is capable of being labelled with 18F for positron emission tomography (PET) imaging.
    MK-3328
  • HY-100290
    5-HT1A modulator 1 142477-34-7
    5-HT1A modulator 1 displays very high affinities for the 5HT1A, adrenergic α1 and dopamine D2 receptor with IC50s of 2 ±0.3 nM, 10 ± 3 nM and 40 ±9 nM, respectively.
    5-HT1A modulator 1
  • HY-100291
    SX-3228 156364-04-4 98%
    SX-3228 is a selective benzodiazepine1 (BZ1) receptor agonist with an IC50 of 17 nM.
    SX-3228
  • HY-100372
    E4CPG 170846-89-6 98.0%
    E4CPG ((RS)-ECPG) is a Group I/Group II metabotropic glutamate receptor (mGluR) antagonist. E4CPG can inhibit the paired-pulse ratio of monosynaptic inhibitory postsynaptic currents (IPSC) potentiation.
    E4CPG
  • HY-100376
    CPI-1189 183619-38-7 99.82%
    CPI-1189 is an orally active TNF-α release inhibitor. CPI-1189 inhibits phosphorylation of p38. CPI-1189 can inhibit apoptosis. CPI-1189 can be used in the study of HIV and neurological diseases.
    CPI-1189
  • HY-100377
    Lvguidingan 82351-05-1 99.48%
    Lvguidingan is a potent anticonvulsant agent. Lvguidingan also has sedative-hypnotic, tranquilizing, and muscle-relaxing actions. Lvguidingan can be used as antiepileptic agent.
    Lvguidingan
  • HY-100379
    Valrocemide 92262-58-3 99.42%
    Valrocemide (TV1901) is a promising antiepileptic agent candidate that shows a broad spectrum of anticonvulsant activity.
    Valrocemide
Cat. No. Product Name / Synonyms Application Reactivity